|
Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Seagen |
Speakers' Bureau - Incyte |
Travel, Accommodations, Expenses - Incyte; Seagen |
| |
|
Honoraria - AngioDynamics; Bayer; Halozyme; Janssen; Pfizer; Pharmacyte Biotech |
Consulting or Advisory Role - Bayer; Halozyme; Janssen; Pfizer; Pharmacyclics; Pharmacyte Biotech; Seagen |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Leap Oncology (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Bayer; Janssen; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Adaptive Biotechnologies; Amgen (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Oncopeptides; Takeda (Inst) |
Research Funding - Abbvie (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Atara Biotherapeutics; Incyte |
Consulting or Advisory Role - Anthem, Inc |
Travel, Accommodations, Expenses - Atara Biotherapeutics; Incyte |